Brokerages Set GH Research PLC (NASDAQ:GHRS) Price Target at $30.38

GH Research PLC (NASDAQ:GHRS) has earned an average rating of “Moderate Buy” from the ten research firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $30.3750.

A number of equities research analysts recently weighed in on the company. Needham & Company LLC assumed coverage on GH Research in a report on Monday, October 13th. They set a “buy” rating and a $19.00 price target for the company. Zacks Research lowered GH Research from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of GH Research in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded GH Research from a “sell” rating to a “hold” rating in a research report on Saturday, July 5th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Osaic Holdings Inc. boosted its position in GH Research by 63.6% in the 2nd quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock valued at $75,000 after buying an additional 2,400 shares during the last quarter. BNP Paribas Financial Markets boosted its position in GH Research by 165.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock valued at $207,000 after buying an additional 10,600 shares during the last quarter. HighVista Strategies LLC bought a new position in shares of GH Research in the 2nd quarter worth $637,000. Stempoint Capital LP acquired a new stake in shares of GH Research during the second quarter worth $1,229,000. Finally, Virtus Investment Advisers LLC acquired a new stake in shares of GH Research during the second quarter worth $89,000. 56.90% of the stock is currently owned by institutional investors.

GH Research Price Performance

GHRS stock opened at $12.76 on Friday. The business has a fifty day moving average price of $13.32 and a 200 day moving average price of $12.59. GH Research has a fifty-two week low of $6.72 and a fifty-two week high of $20.50. The stock has a market capitalization of $663.90 million, a price-to-earnings ratio of -17.24 and a beta of 0.97.

GH Research (NASDAQ:GHRS) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. On average, equities analysts expect that GH Research will post -0.8 earnings per share for the current fiscal year.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).